# Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

> **NCT02013778** · PHASE1,PHASE2 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 8 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** HCQ

## Key facts

- **NCT ID:** NCT02013778
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2018-11
- **Final completion:** 2019-02
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2020-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013778, "Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02013778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*